Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362238 | 0.79 | — | — | |
| SCHEMBL11410484 | 0.74 | LMNA (0.34) | LMNATSHRNPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL5062854 | 0.74 | LMNA (0.34) | LMNATSHRNPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL632188 | 0.74 | LMNA (0.34) | LMNATSHRNPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL16502345 | 0.74 | — | — | |
| SCHEMBL2981814 | 0.73 | LMNA (0.33) | LMNATSHRNPSR1SMN1; SMN2ATM | |
| SCHEMBL9190795 | 0.71 | TSHR (0.32) | LMNATSHRNPSR1CYP2C19KDM4E | |
| SCHEMBL15989261 | 0.70 | HSD11B1 (0.34) | — | |
| SCHEMBL6579528 | 0.69 | ATAD2 (0.33) | — | |
| SCHEMBL162703 | 0.69 | ATAD2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | LMNA 1674/4885TSHR 2854/4885NPSR1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.